Home › Research › Biomarkers
Alzheimer disease blood biomarkers and cognition in midlife
Xiaqing Jiang, Tina Dan My Hoang, Leslie M. Shaw, David R. Jacobs, Ilya M. Nasrallah, R. Nick Bryan, Kristine S. Yaffe. Alzheimer s & Dementia, 2025-12-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Older age, White race, APOE ε4 carrier, and diabetes were associated with biomarker levels indicative of higher AD risk (lower Aβ42/40; higher p-tau217, p-tau217/Aβ42, NfL, and GFAP). After adjustment for age, sex, race, education, body mass index, and estimated glomerular filtration rate, lower Aβ42/40, higher p-tau217, and higher p-tau217/Aβ42 were each associated with worse performance on processing speed and executive function (Figure 1). Higher NfL was associated with worse performance on all five domains, while higher GFAP was associated with worse performance on processing speed and verbal fluency. These associations remained significant after additional adjustment for APOE and cardiovascular risk factors, with no clear pattern for race interaction in biomarker-cognition associations. AD pathology and neurodegeneration indicated by blood biomarkers may already start contributing to cognitive function in midlife. Young and middle adulthood is a critical time for AD prevention, which may delay the onset of cognitive decline and dementia among middle-aged and older adults.
What this study adds
Evidence grade: Low
The record lists 1,356 participants. In midlife adults, blood markers indicating more Alzheimer's pathology and nerve injury were linked to worse performance on tests of processing speed, executive function and other thinking domains. The authors conclude that Alzheimer's-related processes may already affect thinking in midlife, making young and middle adulthood a critical time for prevention efforts.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Jiang, X., Hoang, T. D. M., Shaw, L. M., Jacobs, D. R., Nasrallah, I. M., Bryan, R. N., et al. (2025). Alzheimer disease blood biomarkers and cognition in midlife. Alzheimer s & Dementia. https://doi.org/10.1002/alz70856_101201
Vancouver
Jiang X, Hoang TDM, Shaw LM, Jacobs DR, Nasrallah IM, Bryan RN, et al. Alzheimer disease blood biomarkers and cognition in midlife. Alzheimer s & Dementia. 2025. doi:10.1002/alz70856_101201. PMID: 41447483.
BibTeX
@article{jiang2025-41447483,
author = {Jiang, Xiaqing and Hoang, Tina Dan My and Shaw, Leslie M. and Jacobs, David R. and Nasrallah, Ilya M. and Bryan, R. Nick and Yaffe, Kristine S.},
title = {{Alzheimer disease blood biomarkers and cognition in midlife}},
journal = {Alzheimer s \& Dementia},
year = {2025},
doi = {10.1002/alz70856_101201},
pmid = {41447483},
url = {https://doi.org/10.1002/alz70856_101201}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Older age, White race, APOE ε4 carrier, and diabetes were associated with biomarker levels indicative of higher AD risk (lower Aβ42/40; higher p-tau217, p-tau217/Aβ42, NfL, and GFAP).
- After adjustment for age, sex, race, education, body mass index, and estimated glomerular filtration rate, lower Aβ42/40, higher p-tau217, and higher p-tau217/Aβ42 were each associated with worse performance on processing speed and executive function (Figure 1).
- Higher NfL was associated with worse performance on all five domains, while higher GFAP was associated with worse performance on processing speed and verbal fluency.
- These associations remained significant after additional adjustment for APOE and cardiovascular risk factors, with no clear pattern for race interaction in biomarker-cognition associations.
- AD pathology and neurodegeneration indicated by blood biomarkers may already start contributing to cognitive function in midlife.
Why it matters
In midlife adults, blood markers indicating more Alzheimer's pathology and nerve injury were linked to worse performance on tests of processing speed, executive function and other thinking domains. The authors conclude that Alzheimer's-related processes may already affect thinking in midlife, making young and middle adulthood a critical time for prevention efforts.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants1,356
- Evidence strengthLow
How this study scored 42/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s & Dementia) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 3 / 4 | 1,356 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Kristine S. Yaffe: h-index 155 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of California, San Francisco: institution h-index 1,915 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 5 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41447483) |
| Free to read | 2 / 2 | Free to read |
| Total | 42 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1002/alz70856_101201
- PubMed: 41447483
- Original source →
- Free full text: Alzheimer s & Dementia →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Biomarkers from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.